TrialBreast cancer research : BCR2019

Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.

Yan Xing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.